Bolstering their focus on women’s health, US-based Cosette Pharmaceuticals has acquired the global rights to Intrarosa from Endoceutics, a subsidiary of Endorecherche. Intrarosa is a drug for the treatment of moderate-to-severe dyspareunia, a common symptom of vulvar and vaginal atrophy (VVA) due to menopause. According to Cosette Pharmaceuticals it is unique for being the only prescription drug providing both estrogen and androgen.
The acquisition includes a whopping 108 issued and pending patents worldwide, with the most recent set to expire in 2033. Intrarosa, the heart of the deal, is a unique prescription drug that serves almost all the major markets, including the US, UK, EU, Canada, and Israel. The company’s key distribution partners include industry leaders such as Theramex, Tecnimede, Avia, Lupin, Dexcel, Labatec, Lacer, Lee’s Pharma, and Valenta. Cosette is also eyeing Asian market launches in 2025.
Apurva Saraf, President and CEO of Cosette shared in a statement: “This transformative acquisition further strengthens Cosette’s commitment to women’s health with a patent-protected, novel drug formulation.” Cosette aims to leverage its unique commercial and manufacturing prowess in partnership with MSH Pharma Inc., to ensure continued patient access to Intrarosa. Saraf also expressed the company’s enthusiasm for expanding their global footprint in new territories, alongside their existing distribution partners.
An estimated 64 million post-menopausal women reside in the U.S. alone, with around 32 million of them suffering from VVA symptoms. Various studies have shown that between 44 percent and 78 percent of women with VVA are burdened with dyspareunia.
